SCHEMBL2679643

SCHEMBL2679643

COC(=O)c1ccc(-c2cc(N(COCC[Si](C)(C)C)COCC[Si](C)(C)C)n3ncc(-c4ccc(-c5ccccc5)cc4)c3n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.44
ALDH1A3 P47895 2/20 0.44
ALDH1A2 O94788 1/20 0.44
KDM4E B2RXH2 5/20 0.41
MAPT P10636 4/20 0.41
AHR P35869 1/20 0.40
EGFR P00533 1/20 0.39
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
HPGD P15428 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
HSD17B10 Q99714 3/20 0.38
SGK1 O00141 1/20 0.38
CAMKK2 Q96RR4 1/20 0.38
TTK P33981 2/20 0.37
NTRK1 P04629 1/20 0.37
MET P08581 1/20 0.37
PIM1 P11309 1/20 0.37
FGFR1 P11362 1/20 0.37
MAP2K2 P36507 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL588796 0.86 ALDH1A1 (0.36) ALDH1A1ALDH1A3ALDH1A2KDM4EMAPT
SCHEMBL583745 0.85 DGAT1 (0.40) ALDH1A1ALDH1A3ALDH1A2MAPTHPGD
SCHEMBL2679432 0.81 CCNE1 (0.40) ALDH1A1ALDH1A3KDM4EMAPTNPC1
SCHEMBL7881088 0.79 ALDH1A1 (0.38) ALDH1A1ALDH1A3ALDH1A2KDM4EMAPT
SCHEMBL2679962 0.79 DGAT1 (0.38) ALDH1A1ALDH1A3ALDH1A2KDM4EMAPT
SCHEMBL594353 0.79 DGAT1 (0.37) ALDH1A1ALDH1A3ALDH1A2MAPTSMN1; SMN2
SCHEMBL588542 0.78 DGAT1 (0.39) ALDH1A1KDM4EMAPTAHRNPC1
SCHEMBL10328346 0.78 DGAT1 (0.39) ALDH1A1KDM4EMAPTAHRNPC1
SCHEMBL2680024 0.77 DGAT1 (0.39) ALDH1A1KDM4EMAPTAHRNPC1
SCHEMBL599621 0.77 DGAT1 (0.39) ALDH1A1ALDH1A3ALDH1A2MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8591943-B2 Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2013-11-26 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR ALDH1A1 3479/4885ALDH1A3 4358/4885ALDH1A2 4069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.